Moreover, the patient’s positive response to DPP-4i therapy offers new insights into therapeutic options for NEUROD1-associated MODY6, which has previously been considered primarily insulin dependent. This evidence concerns the gene NEUROD1 and maturity-onset diabetes of the young type 6.